Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 351-358

  Hannani, Dalil ^a,c   Sistigu, Antonella ^a,c,d   Kepp, Oliver ^a,b,c   Galluzzi, Lorenzo ^a,b,c   Kroemer, Guido ^a,b,e,f,g   Zitvogel, Laurence ^a,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Institut Gustave Roussy   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ATP; Calreticulin; dendritic cells; HMGB1; NLRP3; TLR4

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; ANTIGEN; ANTINEOPLASTIC AGENT; CALRETICULIN; CASPASE; CD40 LIGAND; CHLOROQUINE; CRYOPYRIN; CYCLOPHOSPHAMIDE; DNA; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMATINIB; IMMUNOMODULATING AGENT; INFLAMMASOME; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; PROTEIN P57; RECOMBINANT VACCINE; SNARE PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL KILLING; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DNA DAMAGE; DRUG EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INNATE IMMUNITY; LYMPHOMA; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 80053353709     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182325d4d     Document Type: Review

References (93)

1. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;6: 1991-2001. (Pubitemid 351872317)
2. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;1:59-73.
3. Shao H, Cai L, Grichnik JM, et al. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene. 2011;[Epub ahead of print April 25, 2011.].
4. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;8:592-603. (Pubitemid 39025054)
5. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005; 12:1691-1701. (Pubitemid 41815875)
6. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;1:54-61. (Pubitemid 46067386)
7. Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;10:1848-1850. (Pubitemid 47423653)
8. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 4:482-491.
9. Jung S, Unutmaz D,Wong P, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 2002;2:211-220.
10. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;10:1170-1178.
11. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47-59. (Pubitemid 350045573)
12. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798-804.
13. Martins I, Kepp O, Galluzzi L, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2010;1209:77-82.
14. Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;9:1499-1509.
15. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in cell death. EMBO J. 2009;5:578-590.
16. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61-69.
17. Kepp O, Galluzzi L, Giordanetto F, et al. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle. 2009;23:3971-3977.
18. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;1:99-163. (Pubitemid 46209992)
19. Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol. 2008;70:73-91. (Pubitemid 351738172)
20. Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;1:3-11.
21. Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11:700-714.
22. Berwin B, Delneste Y, Lovingood RV, et al. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem. 2004; 49:51250-51257. (Pubitemid 40017869)
23. Duus K, Pagh RT, HolmskovU, et al. Interaction of calreticulin with CD40 ligand, TRAIL and Fas ligand. Scand J Immunol. 2007;5:501-507. (Pubitemid 47609692)
24. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;9:1050-1059. (Pubitemid 47517504)
25. Andersson U,Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;4:565-570. (Pubitemid 30666257)
26. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;6894:191-195. (Pubitemid 34773774)
27. Bell CW, Jiang W, Reich CF III, et al. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006; 6:C1318-C1325. (Pubitemid 44878603)
28. Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;2:321-334. (Pubitemid 41457220)
29. Sancho D, Joffre OP, Keller AM, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009; 7240:899-903.
30. Kepp O, Galluzzi L, Kroemer G. Mitochondrial control of the NLRP3 inflammasome. Nat Immunol. 2011;3:199-200.
31. Franchi L, Eigenbrod T, Munoz-Planillo R, et al. The inflammasome: a caspase-1Yactivation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;3:241-247.
32. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 2010;1:28-33.
33. Chekeni FB, Elliott MR, Sandilos JK, et al. Pannexin 1 channels mediate find-mè signal release and membrane permeability during apoptosis. Nature. 2010;7317:863-867.
34. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;7261:282-286.
35. Majeti R, Alizadeh AA, Tang C, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;2:286-299.
36. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;2:271-285.
37. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63ra94.
38. Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;11:4839-4845. (Pubitemid 46827780)
39. Sancho D, Mourao-Sa D, Joffre OP, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008;6:2098-2110. (Pubitemid 351872329)
40. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;10: 715-727. (Pubitemid 44453458)
41. Mattarollo SR, Loi S, Duret H, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011;14:4809-4820.
42. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 8:1093-1102.
43. Ma Y, Aymeric L, Locher C, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011;3:491-503.
44. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science. 2004;305:197-200. (Pubitemid 38886724)
45. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;6673:245-252. (Pubitemid 28155090)
46. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;6671: 86-89. (Pubitemid 28150594)
47. Russo V, Tanzarella S, Dalerba P, et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A. 2000;5: 2185-2190. (Pubitemid 30134043)
48. Liu K, Iyoda T, Saternus M, et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med. 2002;8:1091-1097. (Pubitemid 35231767)
49. Iyoda T, Shimoyama S, Liu K, et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. 2002;10:1289-1302. (Pubitemid 34564331)
50. Maranon C, Desoutter JF, Hoeffel G, et al. Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2004;16:6092-6097. (Pubitemid 38520533)
51. Blachere NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 2005;6:e185.
52. Hirschowitz EA, Foody T, Kryscio R, et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004;14: 2808-2815. (Pubitemid 41079898)
53. Obeid M, Tesniere A, Panaretakis T, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev. 2007;220:22-34. (Pubitemid 350045569)
54. Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;3:768-778.
55. Pallis AG, Karamouzis MV. DNA repair pathways and their implication in cancer treatment. Cancer Metastasis Rev. 2010;4:677-685.
56. Vitale I, Galluzzi L, Castedo M, et al. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;6:385-392.
57. Galluzzi L, Morselli E, Kepp O, et al. Targeting p53 to mitochondria for cancer therapy. Cell Cycle. 2008;13:1949-1955. (Pubitemid 352030339)
58. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;14:6321-6329. (Pubitemid 40994418)
59. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 7035:864-870. (Pubitemid 40558993)
60. Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;7054:1186-1190. (Pubitemid 41232299)
61. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009;8: 568-580.
62. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 7128:656-660. (Pubitemid 46232886)
63. Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010;4:1111-1124.
64. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores Tand NKeffector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;5:641-648. (Pubitemid 46348738)
65. Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of TH17 cells in cancer patients. Cancer Res. 2011;3:661-665.
66. Proietti E, Greco G, Garrone B, et al. Importance of cyclophosphamideinduced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest. 1998; 2:429-441. (Pubitemid 28067341)
67. Schiavoni G, Mattei F, Di Pucchio T, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 2000;6:2024-2030. (Pubitemid 30151641)
68. Nakahara T, Uchi H, Lesokhin AM, et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010;22:4384-4392.
69. Salem ML, Al-Khami AA, El-Naggar SA, et al. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol. 2010; 4:1737-1747.
70. Salem ML, El-Naggar SA, Cole DJ. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010;2:134-143.
71. Salem ML, Kadima AN, El-Naggar SA, et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007;1:40-53. (Pubitemid 46052202)
72. Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;3:379-388. (Pubitemid 39071610)
73. Menard C, Blay JY, Borg C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;8:3563-3569.
74. Shao C, Folkard M, Michael BD, et al. Targeted cytoplasmic irradiation induces bystander responses. Proc Natl Acad Sci U S A. 2004;37: 13495-13500. (Pubitemid 39238431)
75. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;7:718-726.
76. Formenti SC, Demaria S. Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol. 2008;9:1562-1563; author reply 1563.
77. Meng Y, Carpentier AF, Chen L, et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer. 2005; 6:992-997. (Pubitemid 41209208)
78. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;2:728-734. (Pubitemid 40116901)
79. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 17:5379-5388.
80. Matsumura S,Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;5: 3099-3107.
81. Schaue D, Comin-Anduix B, Ribas A, et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res. 2008;15:4883-4890.
82. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;12:7516-7523. (Pubitemid 40806254)
83. Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010;3:113-124.
84. Ma Y, Conforti R, Aymeric L, et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev. 2011;1:71-82.
85. Matsumura S, Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res. 2010;4:418-425.
86. Sluyter R, Shemon AN, Wiley JS. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol. 2004;6:3399-3405. (Pubitemid 38337918)
87. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;2: 187-191. (Pubitemid 30394990)
88. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;5:504-511.
89. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011;3:1325-1331.
90. Belda-Iniesta C, Ibanez de Caceres I, de Castro J.Monoclonal antibodies for medical oncology: a few critical perspectives. Clin Transl Oncol. 2011; 2:84-87.
91. Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother. 2010; 6:557-569.
92. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11:3353-3362. (Pubitemid 40627887)
93. Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28:4324-4332.